Business
Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg
Second API manufacturing facility added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific regionExpected to improve profitability through manufacturing cost reductions to advance toward the 2030 VisionCost reductions anticipated to begin contributing during 2027 through to the end of 2028 Tokyo, Japan and Cambridge and London, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that Nxera Pharma Japan Co., L
About this update from Nxera Pharma Co., Ltd.
[{"type":"image","alt":"Nxera Pharma","displaySize":"","headline":null,"caption":"Nxera Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MMtO8FGLy1ULu25TBGkF3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638","width":300,"height":101}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Second API manufacturing facility added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific region","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Expected to improve profitability through manufacturing cost reductions to advance toward the 2030 Vision","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Cost reductions anticipated to begin contributing during 2027 through to the end of 2028","length":88,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":338,"olType":false},{"type":"text","content":"Tokyo, Japan and Cambridge and London, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that Nxera Pharma Japan Co., Ltd. (a wholly owned subsidiary of the Company) has received a manufacturing approval partial amendment with respect to QUVIVIQ® (daridorexant) 25 and 50 mg (“the Product”). Daridorexant was launched in Japan as QUVIVIQ® for the treatment of adults with chronic insomnia in December 2024, an application for approval has been submitted for regulatory review in Taiwan, and it is undergoing Phase 3 trials in South Korea.","length":580,"tagName":"p"},{"type":"text","content":"To address the expected growth in demand for QUVIVIQ® in Japan and more broadly across the Asia-Pacific (APAC) region as it becomes available in new markets, Nxera submitted an application to Japan’s Ministry of Health, Labour and Welfare for an approval partial amendment regarding the addition of a manufacturing site in Asia. This approval will enable Nxera to establish a second API manufacturing site in Asia, in addition to its primary API manufacturing site in Europe. The Asian facility will commence operations in phases, with the aim of reducing manufacturing costs through economies ...